title: CardioPulse: The European Medicines Agency's approval of proprotein convertase subtilisin/kexin type 9 inhibitors..
authors: Eberhard
authors: E
authors: Blind
authors: Pieter A
authors: PA
authors: de Graeff
authors: Illiana
authors: I
authors: Meurs
authors: Frank
authors: F
authors: Holtkamp
authors: Ania
authors: A
authors: Baczynska
authors: Heidi
authors: H
authors: Janssen
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D008078:Cholesterol, LDL / Q000187:drug effects; D017277:Drug Approval; D005060:Europe; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy*; D000091362:PCSK9 Inhibitors; D000071449:Proprotein Convertase 9
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D000091362:PCSK9 Inhibitors; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9; C577155:evolocumab; C571059:alirocumab